1. Home
  2. LGHL vs DRMA Comparison

LGHL vs DRMA Comparison

Compare LGHL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LGHL

Lion Group Holding Ltd.

HOLD

Current Price

$3.48

Market Cap

2.2M

Sector

Finance

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.17

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGHL
DRMA
Founded
2015
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LGHL
DRMA
Price
$3.48
$2.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
740.8K
107.6K
Earning Date
04-30-2024
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.32
$2.21
52 Week High
$213.20
$23.70

Technical Indicators

Market Signals
Indicator
LGHL
DRMA
Relative Strength Index (RSI) 49.64 29.93
Support Level $3.32 $2.21
Resistance Level $8.92 $2.98
Average True Range (ATR) 1.15 0.26
MACD -0.30 -0.03
Stochastic Oscillator 2.32 2.91

Price Performance

Historical Comparison
LGHL
DRMA

About LGHL Lion Group Holding Ltd.

Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: